MTFP1 and metabolic dysfunction-associated steatohepatitis: Currently, there is limited information on the beneficial effects in the liver of boosting both Complex IV and V activities concomitantly and further studies are currently underway to determine the breadth of protection that MTFP1 ablation in hepatocytes confers in the context of NASH and may prove useful for the in vivo exploration and development of therapeutic targets for other inherited and acquired liver diseases.